RhoVac Seeks Path Forward After Phase IIb Prostate Cancer Disappointment
Executive Summary
Despite a seemingly sound mechanism and promising early data, the Swedish firm’s sole clinical asset has flunked a mid-stage prostate cancer trial, prompting a search for responsive subgroups.